Symbiotec Pharmalab IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 723.33 | 755.98 | 872.26 |
| Expense | 590.99 | 608.85 | 709.90 |
| Profit (PAT) | 100.06 | 96.79 | 109.90 |
| Total Assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Concord Biotech Limited | 24.78 | 61.07 | 14.00 | - | 1,054.90 Cr |
| Divi’s Laboratories Limited | 96.75 | 87.80 | 16.50 | 631.00 | 10,560.00 Cr |
| Cohance Lifesciences Limited | 4.69 | 95.02 | 7.00 | - | 2,268.55 Cr |
| Laurus Labs Limited | 16.47 | 109.36 | 16.80 | - | 6,812.90 Cr |
Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP
Strengths & Risks
- Heavily oversubscribed — 75.1x overall (so far).
- Strong institutional (QIB) demand — 181.2x.
- Revenue grew 15% in the latest reported year.
- Solid profit margin — 12.6%.
- Largely an offer for sale — most proceeds go to selling shareholders, not the company.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience. It mainly manufactures Corticosteroid and Steroidal Hormone APIs, which are important ingredients used to make medicines. The company has grown from a small laboratory-scale steroid manufacturer into a fully integrated global company. In FY2025, Symbiotec had a strong share of the global market for these APIs and was the only Indian and global company present across the top 10 categories in this market. In FY2025, they were a global leader by volume in the production of Corticosteroid and Steroidal-Hormone Active Pharmaceutical Ingredients (APIs).
Symbiotec Pharmalab Ltd., 385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331
| Purpose | Amount (Cr) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| General corporate purposes | - |
Resources & Documents
Symbiotec Pharmalab has set a price band of Rs 938–Rs 988 per share for an issue size of Rs 1,757 crore. The stock listed flat against its issue price.
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience. It mainly manufactures Corticosteroid and Steroidal Hormone APIs, which are important ingredients used to make medicines.
The issue is promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP with JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Co… (Rs 113 crore) and General corporate purposes.
On fundamentals, the company is posting revenue growth of 15.4%, a profit margin of 12.6%, return on equity of 11.2% in its most recent reported period. Listed peers in this segment include Concord Biotech Limited (P/E 61.07x) and Divi’s Laboratories Limited (P/E 87.80x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Symbiotec Pharmalab IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Symbiotec Pharmalab GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!